Clinical Trial Update: A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins

View source ↗

Summary

A completed clinical trial update assessing how many patients develop pure red cell aplasia while receiving epoetin alfa or other recombinant erythropoietins.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pure Red Cell Aplasia

Drugs mentioned

• Epogen (epoetin alfa)
• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Red-Cell Aplasia, Pure | Status: COMPLETED